Embed Size (px)
Citation preview
Cancer Centers Program Update and Future Directions
Linda K. Weiss, PhDDirector, Office of Cancer Centers
Cancer Center Administrators ForumApril 5, 2011
http://[email protected]
Overview
• Portfolio• FY 2010 Funding, Parent Grant and Special Initiatives • FY 2011 Budget• Organizational Changes• Database, Website, and Centers Report• Miscellaneous Items• Program Announcement 11-005• Cancer Center Support Grant Guidelines: Where Next?
Portfolio
• Geographic Distribution of Cancer Centers– 66 Centers in 33/50 states and DC– 40 Comprehensive: 23 states and DC– 26 Cancer Centers: 17 states: 17 states
STATE POPULATIONDENSITY LEGEND
< 87 people per sq mile
87 - 149 people per sq mile
150 - 249 people per sq mile
250 - 499 people per sq mile
> 500 people per sq mile
2009 State Population Densityand NCI-designated Cancer Center Location
95
237
100
7
19
40
2434
58 17
6
49
11
9
23
35
54
66
104
54
87
233
56
104
176
179
43
63 93
153
283
171
346
193152
109 20076
282
41568
587 - MD1,184 - NJ
845
727 - CT
454 - DE
1,018 - RI
9,815 - DC
1
202
CENTER LEGEND
Cancer Center (26)
ComprehensiveCenter (40)
148 - NH
New1%, $1.5 M Competing
$43.2 M, 16%
Extensions$50.0 M, 18%Non-
Competing$177.0 M, 65%
CCSG Funding By Application Type, FY2010, $271,490,840 Total Costs, Parent Grant
FY 10 Funding for Special Initiatives
• Supplemental Initiatives through OCC: $7.4 M– Ca BIG: 0.8 M– AMC: 1.0 M– CFAR: 1.5 M– NCCCP: 0.8 M– RaPID: 3.0 M– Miscellaneous: 0.6 M
• Additional Supplements– CTRP (NCI CCCT): 5.2 M– Core Consolidation (NCRR): 8.0 M
FY 2011 Budget
• Centers Baseline Budget– Continuing Resolution
now in effect until 4/8– Centers budget has not
been finalized– T3/5 funded under NIH
policy at 90%– T1/2 budget pending
• Anticipated Supplements– Clinical Investigator
Team Leadership Award
– Clinical Trials Reporting Program
– CFAR – CC Pilot Project Awards
– AMC – CC Pilot Project Awards
Organizational Changes • New NCI Leadership
– Dr. Harold Varmus, Director– Dr. Douglas Lowy, Deputy Director– Dr. Peter Greenwald, Associate Director for Prevention and Control– John Czajkowski, Deputy Director for Management– Searches underway
• Associate Director for Clinical Research• Director Center for Center for Cancer Genomics• Director for Center for Global Health• Director for Division of Cancer Prevention
• Office of Cancer Centers New Staff– Nga Nguyen, Program Analyst– Searches underway
• Program Director• IT Database Specialist
Database, Website and Centers Report• Summaries
– Send as before to [email protected]– Send content questions to your program director
• Website Updates– Send center name, address, directorship changes to your
program director– More complex changes will be deferred
• Centers Report– Nearing completion – Some information will be web-based (e.g., publications,
clinical trials)
Miscellaneous Items• Include PMCID numbers with publications list• Large carryover balances are discouraged, particularly
as a repeated pattern; there is no guaranteed approval• Fewer administrative supplements (extensions with
funds) than in previous years, no ‘recycling’• New programs and shared resources can’t be
established with CCSG funds during non-competing years; realigned programs must be approved by staff
Program Announcement 11-005
• Overview Opportunity Announcement
– Effective September 25, 2010, NIH required that all mechanisms have a Funding Opportunity Announcement in the NIH Guide for Grants and Contracts
– All applications will have to respond to the PAR
– The PAR, new Guidelines, and a comparison of 2008 and 2010 Guidelines are on our website.
Program Announcement 11-005
• Face page of the application must indicate the PAR #• Resubmission applications (A1) now allowed within 37
months• New page limits for components are in effect• Appendices must be included in the application and
can’t exceed 50 pages• Late materials must follow NIH policy – much more
stringent limitations • Submission procedures for letter of approval and
request for preliminary information have changed
Program Announcement 11-005
• Applicants will no longer receive and respond to an administrative review letter
• Applicants will no longer submit posters and updated summaries prior to the site visit; information not provided in the original application can be provided at the site visit.
• The SRO can no longer selectively accept parts of the application
• The application can be returned without review if it doesn’t meet guidelines requirements
Program Announcement 11-005
– The 5 review criteria mandated by NIH (significance, investigator, innovation, approach and environment) are now incorporated into the Guidelines.
– The 5 criteria will be incorporated into the evaluation of overall center impact but not individual components
– Prior to the site visit assigned reviewers will submit criterion scores for the overall application on the 5 NIH mandated criteria. These scores will be in the summary statement, but won’t be discussed at the review.
– The 6th year of funding for centers scoring in the outstanding range has been eliminated.
– NIH policy and document citations have been updated.
The CCSG Guidelines: Where Next?
• Major Objectives– Foster collaboration and integration– Facilitate clinical and translational research– Reduce the burden of the application process– Provide new guidance on eligibility and budget requests
The CCSG Guidelines: Where Next?
• Foster Collaboration and Integration– Recognize research collaborations that extend beyond
the walls of the center, including ‘hand-offs’ to other mechanisms or entities that move scientific findings forward
– Encourage productive interactions with other NCI and NIH programs
– Allow sharing of core services across centers– Eliminate the benchmark ratio
The CCSG Guidelines: Where Next?
• Facilitate Clinical and Translational Research– Make Clinical Trial and Data Management (the CTO) a
separate component and broaden options for support – Harmonize guidelines to recognize leadership and
participation in the cooperative groups– Recognize variety and quality in clinical and translational
research– Promote team contributions in clinical research
The CCSG Guidelines: Where Next?
• Reduce the Burden of the Application Process– Eliminate
• multiple redundancies across components• detailed capacity and usage tables in shared resource
components• data on non-aligned members• requirements for program meeting agendas
– Streamline • clinical and other data requirements• requirements for the administrative component
The CCSG Guidelines: Where Next?
• Provide New Guidance on Eligibility and Budget– Raise eligibility minimum, e.g., from $4 to $10 M– Budget Requests
• Base request on percent over prior award or a minimum level or ‘floor’ whichever is greater, e.g.,
– 20% over last T5 award or $2 M DC• Allow for exceptions, e.g.,
– First T2– First application after no-cost extension– Major expansion of research
• Funding level would still be dependent on merit and NCI budget
The CCSG Guidelines: Where Next?
• Other Potential Changes– More specificity in language for consortium centers– Expansion/redefinition of staff investigator category– Modification in criteria for Protocol specific resaerch
support – Elimination of the limited site visit
The CCSG Guidelines: Where Next?
• Process– Collaborators/Consultants
• NCI– Review– Grants Administration– Senior leadership
• Cancer Centers
– Approvals • NCI senior leadership• NCAB Subcommittee on Cancer Centers• NIH (to include a new PAR)
• Tentative timeline for implementation: 2012
QUESTIONS?Questions?
